{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-24-000053","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2024-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.720847+00:00","generated_at":"2026-06-06T04:50:28.788064+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"medium","headline":"Regen Biopharma files provisional patent for stem cell endothelial therapy to speed hematopoietic recovery","bullets":["Filed a provisional patent application with the USPTO on February 7, 2024.","Covers compositions, protocols, and treatment means for accelerating hematopoietic reconstitution.","Targets recovery after insult or chronic pathology using stem cell-derived endothelial progenitor or endothelial cells.","Application protects a potential regenerative medicine therapy for bone marrow or blood cell restoration."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-24-000053","json":"https://secwatch.observer/filing/0001607062-24-000053.json","markdown":"https://secwatch.observer/filing/0001607062-24-000053.md","text":"https://secwatch.observer/filing/0001607062-24-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706224000053/0001607062-24-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706224000053/rgbp020924form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:50:28.788064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}